Phase 2 study of docetaxel in the treatment of childhood refractory acute leukemias: a Children's Oncology Group report.
Pediatr Blood Cancer
; 50(3): 533-6, 2008 Mar.
Article
em En
| MEDLINE
| ID: mdl-17668867
ABSTRACT
BACKGROUND:
To determine the response rate and toxicity of docetaxel when administered as a 60 mg/m(2) dose by 1 hr intravenous (IV) infusion weekly x 3 weeks in children with relapsed acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). PROCEDURE Patients who were under the age of 22-year-old at the time of the original ALL or AML diagnosis and in a second relapse were accrued from August 2002 to May 2005 for this Children's Oncology Group (COG) phase 2 study (ADVL0023). Ten patients with ALL and two patients with AML were enrolled.RESULTS:
There were no complete or partial responses observed. The most common grade 3 or 4 toxicities were hematologic followed by febrile neutropenia. One patient developed a dose limiting elevation in serum bilirubin, but no other significant hepatotoxicity was observed.CONCLUSIONS:
Docetaxel was not effective therapy for children with relapsed ALL at the dose and schedule tested.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia
/
Terapia de Salvação
/
Taxoides
/
Antineoplásicos Fitogênicos
Tipo de estudo:
Etiology_studies
Limite:
Adolescent
/
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article